RecruitingNot ApplicableNCT06261658

Improving the Quality of Cryopreserved Ovarian Tissue Reimplantation Using Platelet-enriched Autologous Plasma

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Enrollment

45 participants

Start Date

Mar 1, 2024

Study Type

INTERVENTIONAL

Conditions

Cryopreservation Infertility, Female Ovary Injury Menopause Ovarian Failure

Summary

The study is aimed to evaluate the effects of intraovarian injection of autologous Platelet-enriched Autologous Plasma on the outcomes of orthotopic transplantation of cryopreserved ovarian tissue.

Eligibility

Sex: FEMALE

Inclusion Criteria7

request for cryopreserved ovarian tissue transplantation;
premature ovarian failure or irregular mentrual cycles;
negative test for HIV, HBV, HCV, Treponema pallidum;
negative PAP test;
oncological authorization;
absence of neoplastic contamination in the cryopreserved ovarian tissue;
Informed consent

Exclusion Criteria8

neoplastic contamination in cryopreserved ovarian tissue;
history of endometriosis;
endocrinological disorders present and not treated (uncompensated thyroid dysfunction, diabetes (type 1, type 2);
body mass index (BMI) \>30 kg/m2;
circulating platelet level \< 150,000 / mml;
bacterial infection;
ongoing use of anticoagulants;
bleeding diathesis.

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.